A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.

被引：0
|
作者：
Li, Ningning
Ge, Yuping
Wang, Xiang
Qiu, Wei
Zhang, Zhiyang
Zhou, Na
Zhao, Lin
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll Hosp, Dept Med Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-374; 283-424-6846-271-2644; 298-145-222-7468; 261-566-148; 130-540-543-4790; 613-135-244-3829-325; 261-492-2769; 4; 3; 2; 2461; 6;
D O I：
10.1200/JCO.2024.42.3_suppl.323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：323 / 323
页数：1
相关论文
共 50 条
  • [41] Comparative analysis of profiles of second-line stage IV renal cell carcinoma patients by first-line to second-line treatment sequencing in the United States.
    DaSilva, Corrina
    Spindel, Julie
    Franceschetti, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma
    Li, Xuyuan
    Lin, Wen
    Wang, Hongbiao
    Lin, Wenzhao
    Lin, Suiling
    Lin, Yingcheng
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [43] Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma
    Xuyuan Li
    Wen Lin
    Hongbiao Wang
    Wenzhao Lin
    Suiling Lin
    Yingcheng Lin
    Medical Oncology, 2013, 30
  • [44] Phase II study of S-1 in combination with paclitaxel as a first-line treatment for patients with advanced/recurrent gastric cancer
    Toh, U.
    Yamana, H.
    Koufuji, K.
    Mine, T.
    Aoyagi, K.
    Miyagi, M.
    Imaizumi, T.
    Shirouzu, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer
    Chikara Kunisaki
    Masazumi Takahashi
    Hirochika Makino
    Takashi Oshima
    Shoichi Fujii
    Ryo Takagawa
    Jun Kimura
    Takashi Kosaka
    Hidetaka A. Ono
    Hirotoshi Akiyama
    Kunio Kameda
    Fumihiko Kito
    Satoshi Morita
    Itaru Endo
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1363 - 1368
  • [46] Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer
    Kunisaki, Chikara
    Takahashi, Masazumi
    Makino, Hirochika
    Oshima, Takashi
    Fujii, Shoichi
    Takagawa, Ryo
    Kimura, Jun
    Kosaka, Takashi
    Ono, Hidetaka A.
    Akiyama, Hirotoshi
    Kameda, Kunio
    Kito, Fumihiko
    Morita, Satoshi
    Endo, Itaru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1363 - 1368
  • [47] The Efficiency and Safety of Apatinib plus S-1 as Second-Line or Laterline Chemotherapy for Advanced Squamous Cell Lung Carcinoma
    Shi, Q.
    Guo, X.
    Wang, Z.
    Cheng, X.
    Xia, L.
    Li, X.
    Hu, W.
    Zhao, F.
    Liu, Y.
    Wang, J.
    Wang, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2072 - S2072
  • [48] Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma
    Rogers, Jane E.
    Yamashita, Kohei
    Sewastjanow-Silva, Matheus
    Rosa Vicentini, Ernesto
    Waters, Rebecca
    Ajani, Jaffer A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (06) : 565 - 571
  • [49] Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FUTURE ONCOLOGY, 2020, 16 (17) : 1189 - 1198
  • [50] S-1 Monotherapy as Second- or Third-Line Chemotherapy for Unresectable and Recurrent Esophageal Squamous Cell Carcinoma
    Akutsu, Yasunori
    Kono, Tsuguaki
    Uesato, Masaya
    Hoshino, Isamu
    Narushima, Kazuo
    Hanaoka, Toshiharu
    Tochigi, Toru
    Semba, Yoshihide
    Qin, Wei
    Matsubara, Hisahiro
    ONCOLOGY, 2013, 84 (05) : 305 - 310
12345